Order Article Reprints

Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Muñoz E, Rodríguez-Serrano EM, Martínez Ávila JC, Salinas-Muñoz L, Serrano-Huertas S, Ferreiro R, et al. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers. 2021; 13(7):1710. https://doi.org/10.3390/cancers13071710

Conde, Elisa, Julie Earl, Lorena Crespo-Toro, Carolina Blanco-Agudo, Edurne Ramos-Muñoz, E. Macarena Rodríguez-Serrano, Jose Carlos Martínez Ávila, Laura Salinas-Muñoz, Silvia Serrano-Huertas, Reyes Ferreiro, and et al. 2021. "Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study" Cancers 13, no. 7: 1710. https://doi.org/10.3390/cancers13071710

Conde, E., Earl, J., Crespo-Toro, L., Blanco-Agudo, C., Ramos-Muñoz, E., Rodríguez-Serrano, E. M., Martínez Ávila, J. C., Salinas-Muñoz, L., Serrano-Huertas, S., Ferreiro, R., Rodriguez-Garrote, M., Sainz, B., Jr., Massuti, B., Alfonso, P. G., Benavides, M., Aranda, E., García-Bermejo, M. L., & Carrato, A. (2021). Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers, 13(7), 1710. https://doi.org/10.3390/cancers13071710